These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 3273886)

  • 21. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression.
    Feighner JP; Herbstein J; Damlouji N
    J Clin Psychiatry; 1985 Jun; 46(6):206-9. PubMed ID: 3997787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoamine oxidase inhibitors revisited: what you should know.
    Goldberg JF; Thase ME
    J Clin Psychiatry; 2013 Feb; 74(2):189-91. PubMed ID: 23473352
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of chronic phenelzine treatment on REM sleep: report of three patients.
    Landolt HP; de Boer LP
    Neuropsychopharmacology; 2001 Nov; 25(5 Suppl):S63-7. PubMed ID: 11682276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 'Spontaneous' hypertensive episodes with monoamine oxidase inhibitors.
    Fallon B; Foote B; Walsh BT; Roose SP
    J Clin Psychiatry; 1988 Apr; 49(4):163-5. PubMed ID: 3281932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Central nervous system toxicity after abrupt monoamine oxidase inhibitor switch: a case report.
    Safferman AZ; Masiar SJ
    Ann Pharmacother; 1992 Mar; 26(3):337-8. PubMed ID: 1554951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report.
    Clemons WE; Makela E; Young J
    Sleep Med; 2004 Sep; 5(5):509-11. PubMed ID: 15341899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressant-refractory depression.
    Tulen JH; Volkers AC; van den Broek WW; Bruijn JA
    J Clin Psychopharmacol; 2006 Oct; 26(5):542-4. PubMed ID: 16974207
    [No Abstract]   [Full Text] [Related]  

  • 28. The safety of switching rapidly from tricyclic antidepressants to monoamine oxidase inhibitors.
    Kahn D; Silver JM; Opler LA
    J Clin Psychopharmacol; 1989 Jun; 9(3):198-202. PubMed ID: 2738181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tap (draft) beer and monoamine oxidase inhibitor dietary restrictions.
    Shulman KI; Tailor SA; Walker SE; Gardner DM
    Can J Psychiatry; 1997 Apr; 42(3):310-2. PubMed ID: 9114949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
    Adli M; Pilhatsch M; Bauer M; Köberle U; Ricken R; Janssen G; Ulrich S; Bschor T
    Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversible Cerebral Vasoconstriction Syndrome and Monoamine Oxidase Inhibitors.
    Durmuş B; Osse RJ; Emmer B; van Kooten F
    Prim Care Companion CNS Disord; 2016 Dec; 18(6):. PubMed ID: 27922229
    [No Abstract]   [Full Text] [Related]  

  • 32. The selective reversible monoamine oxidase-A inhibitor brofaromine and sleep.
    Hoffmans J; Knegtering R
    J Clin Psychopharmacol; 1993 Aug; 13(4):291-2. PubMed ID: 8376621
    [No Abstract]   [Full Text] [Related]  

  • 33. [Adverse drug reactions in combined treatment with tricyclic antidepressants and monoamine oxidase inhibitors].
    von Oefele K; Grohmann R; Hippius H; Rüther E
    Nervenarzt; 1988 Feb; 59(2):118-23. PubMed ID: 3362260
    [No Abstract]   [Full Text] [Related]  

  • 34. Mysterious MAOI hypertensive episodes.
    Linet LS
    J Clin Psychiatry; 1986 Nov; 47(11):563-5. PubMed ID: 3095312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brofaromine in treatment-resistant depressed patients--a comparative trial versus tranylcypromine.
    Volz HP; Faltus F; Magyar I; Möller HJ
    J Affect Disord; 1994 Mar; 30(3):209-17. PubMed ID: 8006247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients.
    Birkenhäger TK; van den Broek WW; Mulder PG; Bruijn JA; Moleman P
    J Clin Psychiatry; 2004 Nov; 65(11):1505-10. PubMed ID: 15554763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of monoamine oxidase inhibitor-associated insomnia with trazodone.
    Nierenberg AA; Keck PE
    J Clin Psychopharmacol; 1989 Feb; 9(1):42-5. PubMed ID: 2708555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse reactions to monoamine oxidase inhibitors. Part II. Treatment correlates and clinical management.
    Rabkin JG; Quitkin FM; McGrath P; Harrison W; Tricamo E
    J Clin Psychopharmacol; 1985 Feb; 5(1):2-9. PubMed ID: 3973068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Not all monoamine oxidase inhibitors are created equal.
    Stewart JT
    J Am Geriatr Soc; 2007 Nov; 55(11):1890. PubMed ID: 17979910
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.